Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the NF-κB pathway represents a potential strategy to attenuate HGF-induced resistance to KRAS G12C inhibitors in lung adenocarcinoma.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Apr 2026

Jiao Demin, Chen Yu, Liu Xiang, Xu Wei, Tang Xiali, Chen Jun, Yan Li, Chen Qingyong

Abstract excerpt

PURPOSE: This study aims to investigate the role of hepatocyte growth factor (HGF) overexpression in mediating resistance to KRAS G12C inhibitors in lung adenocarcinoma and to explore potential combination therapies to attenuate this resistance. METHODS: Lentiviral transfection was used to establish HGF-overexpressing lung adenocarcinoma cell lines harboring the KRAS G12C mutation (H23 and H358). Cells were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Hepatocyte Growth Factor

Share to Lung Neoplasms

Share to NF-kappa B

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 41046503
DOI: 10.1007/s12094-025-04067-w

Genes

HGF
KRAS
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the NF-κB pathway represents a potential strategy to attenuate HGF-induced resistance to KRAS G12C inhibitors in lung adenocarcinoma.PMID 41046503Read ↗

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.Semantic proximity Read ↗

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.Semantic proximity Read ↗

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.Semantic proximity Read ↗

Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.Semantic proximity Read ↗

Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.Semantic proximity Read ↗

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.Semantic proximity Read ↗

Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.Semantic proximity Read ↗

TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.Semantic proximity Read ↗

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.Semantic proximity Read ↗

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.Semantic proximity Read ↗

Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.